Growth hormone treatment in children on chronic glucorticoid therapy

Endocrine Development

Volumn 20, Issue , 2010, Pages 194-201

  Savage, Martin O ^a   Simon, Dominique ^b   Czernichow, Paul C ^c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYTOKINE; GLUCOCORTICOID; GROWTH HORMONE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; SOMATOMEDIN C; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; BIOSYNTHESIS; CHILDHOOD DISEASE; CORTICOSTEROID THERAPY; CROHN DISEASE; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG EFFICACY; ENTERIC FEEDING; GROWTH DISORDER; GROWTH HORMONE RELEASE; HUMAN; INFLAMMATION; JUVENILE RHEUMATOID ARTHRITIS; NONHUMAN; NUTRITIONAL DEFICIENCY; PRIORITY JOURNAL; PUBERTY; TREATMENT DURATION;

ADULT; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; GLUCOCORTICOIDS; GROWTH DISORDERS; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; MODELS, BIOLOGICAL; TIME FACTORS;

EID: 78751480250     PISSN: 14217082     EISSN: 16622979     Source Type: Book Series    
DOI: 10.1159/000321245     Document Type: Article

References (19)

1. Heuschkel R, Salvestrini C, Beattie RM, Hildebrand H, Walters TD, Griffiths A: Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm Bowel Dis 2008;14: 839-849.
2. Walters TD, Griffiths AM: mechanism of growth impairment in pediatric Crohns disease. Nat Rev Gastroenterol Hepatol 2009;6:513-523.
3. Simon D, Fernando C, Czernichow PC, Prieur AM: Linear growth and final height in patients with systemic juvenile chronic arthritis treated with long-term glucocorticoids. J Rheumatol 2002;29:1296-1300.
4. Thissen J-P: How proinflammatory cytokines may impair growth and cause muscle wasting. Horm Res 2007;67(suppl 1):64-70.
5. Sawczenko A, Azooz O, Paraszczuk J, Idestrom M, Croft NM, Savage MO, Ballinger AB, Sanderson IR: Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the -174 IL-6 G/C polymorphism in children. Proc Natl Acad Sci USA 2005;102:13260-13265.
6. Davies UM, Jones J, Reeve J, Camacho-Hubner C, Charlett A, Ansell BM, Preece MA, Woo P: Juvenile rheumatoid arthritis: effects of disease activity and recombinant human growth hormone on insulinlike growth factor 1, insulin-like growth factor binding proteins 1 and 3 and osteocalcin. Arthritis Rheum 1997;40:332-340.
7. Street ME, De Angelis GL, Camacho-Hubner C, Giovanelli G, Ziveri MA, Bacchini PL, Bernasconi S, Sansebastiona G, Savage MO: Relationships between serum IGF-I, IGFBP-2, interleukin-1β and interleukin-6 in inflammatory bowel disease. Horm Res 2004;61:159-164.
8. Macrae VE, Wong SC, Farquarson C, Ahmed SF: Cytokine actions in growth disorders associated with pediatric chronic inflammatory diseases. Int J Mol Med 2006;18:1011-1018.
9. Mushtaq T, Ahmed SF: The impact of corticosteroids on growth and bone health. Arch Dis Child 2002;87:93-96.
10. Simon D, Prieur A-M, Quartier P, Ruiz JC, Czernichow P: Early recombinant human growth hormone treatment in glucocorticoid-treated children with juvenile idiopathic arthritis: a 3-year randomized study. J Clin Endocrinol Metab 2007;92; 2567-2573.
11. Bismuth E, Chevenne D, Czernichow PC, Simon D: Moderate deterioration in glucose tolerance during high-dose growth hormone therapy in glucocorticoidtreated patients with juvenile idiopathic arthritis. Horm Res Paediatr 2010;73:465-472.
12. Bechtold S, Ripperger P, Dalla Pozza R, Bonfig W, Hafner R, Michels H, Schwarz HP: Growth hormone increases final height in patients with juvenile idiopathic arthritis: data from a randomized controlled study. J Clin Endocrinol Metab 2007;92:3013-3018.
13. Bechtold S, Ripperger P, Dalla Pozza R, Roth J, Hafner R, Michels H, Schwarz HP: Dynamics of body composition and bone in patients with juvenile idiopathic arthritis treated with growth hormone. J Clin Endocrinol Metab 2010;95:178-185.
14. Sawczenko A, Sandhu B: Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child 2003;88:995-1000.
15. Wong SC, Smyth A, McNeill E, Galloway PJ, Hassan K, McGrogan P, Ahmed SF: The growth hormoneinsulin-like growth factor-1 axis in children and adolescents with inflammatory bowel disease and growth retardation. Clin Endocrinol (Oxf) 2010;73:220-228.
16. Sawczenko A, Ballinger AB, Savage MO, Sanderson IR: Clinical features affecting final adult height in patients with pediatric-onset Crohns disease. Pediatrics 2006;118:124-129.
17. Walters TD, Gilman AR, Griffiths AM: Linear growth improves during infliximab therapy in children with chronically active severe Crohns disease. Inflamm Bowel Dis 2007;4:424-430.
18. Mauras N, George D, Evans J, Milov D, Abrams S, Rini A, Welch S, Haymond MW: Growth Hormone has anabolic effects in glucocorticoid-dependent children with inflammatory bowel disease: a pilot study. Metabolism 2002;51:127-135.
19. Heyman MB, Garnett EA, Wojcicki J, Gupta N, Davis C, Cohen SA, Gold B, Kirschner BS, Baldassano RN, Ferry GD, Winter HS, Kaplan S: Growth hormone treatment of growth failure in pediatric patients with Crohns disease. J Pediatr 2008;153:651-658.